Clinical Trials Logo

Non-Hodgkin's Lymphoma clinical trials

View clinical trials related to Non-Hodgkin's Lymphoma.

Filter by:

NCT ID: NCT00100347 Terminated - Solid Tumors Clinical Trials

Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin’s Lymphoma and Solid Tumors

Start date: December 2004
Phase: Phase 1
Study type: Interventional

The purpose of this multi-center, open-label, escalating dose study is to assess the safety and tolerability of PPI-2458 in subjects with Non-Hodgkin's Lymphoma (NHL)and solid tumors. Subjects will be treated every other day (QOD) with PPI-2458 while being monitored closely for adverse events.

NCT ID: NCT00077961 Terminated - Clinical trials for Non-Hodgkin's Lymphoma

Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

Start date: December 2003
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the optimal dose of subcutaneous CAMPATH when used in combination with rituximab for patients with relapsing or refractory, low-grade or follicular, CD-20-positive, B-Cell non-Hodgkin's Lymphoma. Safety will be the primary objective of phase I, while the primary objective of phase II will be to determine overall response.

NCT ID: NCT00057447 Terminated - Clinical trials for Non-Hodgkin's Lymphoma

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

Start date: March 2003
Phase: Phase 1/Phase 2
Study type: Interventional

Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL) International study with sites in the Czech Republic and Poland

NCT ID: NCT00057343 Terminated - Clinical trials for Non-Hodgkin's Lymphoma

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

Start date: March 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease.

NCT ID: NCT00043459 Terminated - Clinical trials for Non-Hodgkin's Lymphoma

Study of T900607-Sodium in Previously Treated Patients With Non-Hodgkin's Lymphoma.

Start date: July 2002
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine whether T900607-sodium is effective and safe in treating non-Hodgkin's lymphoma.

NCT ID: NCT00038818 Terminated - Multiple Myeloma Clinical Trials

CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation

Start date: May 2001
Phase: N/A
Study type: Interventional

Primary Objectives: To evaluate response rates of acute or chronic Graft-versus-host disease (GVHD) following CD8 depleted DLI (Depleted Donor Lymphocyte Infusions) in patients with Chronic myelomonocytic leukemia (CMML), chronic lymphoid leukemia (CLL), Non-Hodgkin's lymphoma (NLM), Multiple Myeloma (MM) and Hodgkin's Lymphoma (HD). Secondary Objectives: - To evaluate safety and treatment related mortality after CD8 depleted DLI. - To evaluate the time to onset of GVHD following DLI and response to GVHD treatment. - To evaluate the incidence and timing of pancytopenia following DLI. - To evaluate disease-free survival, overall survival and relapse rates in three cohorts of patients; early relapse CML, late relapse CML and lymphoproliferative disorders (HD, CLL, NHL and MM). - To evaluate the need and efficacy of second or subsequent CD8 depleted donor lymphocyte infusions. - To evaluate the number of apheresis procedures needed to collect appropriate doses of CD4+ cells.

NCT ID: NCT00038779 Terminated - Leukemia Clinical Trials

Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States

Start date: August 14, 1996
Phase: N/A
Study type: Interventional

The purpose of this study is to assess early treatment failure within 100 days and to assess the effect of this regimen on engraftment, GVHD, immune recovery, relapse of malignancy and survival.